Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
By emalexadmin |
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.